Prevalence of and Reasons for Discontinuation of Continuous Subcutaneous Insulin Infusion in People with Type 1 Diabetes: A Systematic Review

Pim Dekker*, Henk Jan Aanstoot, Theo Sas, Martine de Vries, Erwin Birnie, Dick Mul, Giesje Nefs

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

3 Citations (Scopus)

Abstract

The introduction of continuous subcutaneous insulin infusion in clinical care has led to more optimal glycemic and quality-of-life outcomes, compared with multiple daily injections (MDI). Despite this, some insulin pump users revert back to MDI. The aim of this review was to include the most recent rates of insulin pump discontinuation among people with type 1 diabetes and to identify reasons for and factors associated with discontinuation. A systematic literature search was conducted using the Embase.com, MEDLINE (via OVID), PsycINFO, and CINAHL databases. Titles and abstracts of eligible publications were screened, and baseline characteristics of the included studies were extracted, as were variables in the context of insulin pump use. Data were synthesized into themes: indications for insulin pump initiation, persons with type 1 diabetes (PWD)-reported reasons for, and factors associated with insulin pump discontinuation. A total of 826 eligible publications were identified and 67 were included. Discontinuation percentages ranged from 0% to 30% (median 7%). The most frequently mentioned reasons for discontinuation were wear-related issues (e.g., device attached to the body, interference with daily activities, discomfort, affected body image). Related factors included hemoglobin A1c (HbA1c) (17%), issues with following treatment recommendations (14%), age (11%), gender (9%), side effects (7%), and comorbidity- and complication-related factors (6%). Despite many developments in insulin pump technology, discontinuation rates and PWD-reported reasons for and factors associated with insulin pump discontinuation in more recent studies were comparable to earlier reviews/meta-analyses. Continuation of insulin pump treatment depends on a knowledgeable and willing health care provider (HCP) team and a close match with PWDs' wishes and needs.

Original languageEnglish
Pages (from-to)559-570
Number of pages12
JournalDiabetes Technology & Therapeutics
Volume25
Issue number8
DOIs
Publication statusPublished - 31 Jul 2023

Bibliographical note

Publisher Copyright:
© Mary Ann Liebert, Inc.

Fingerprint

Dive into the research topics of 'Prevalence of and Reasons for Discontinuation of Continuous Subcutaneous Insulin Infusion in People with Type 1 Diabetes: A Systematic Review'. Together they form a unique fingerprint.

Cite this